𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-grade gliomas in patients with prior systemic malignancies

✍ Scribed by Fernando C. Maluf; Lisa M. DeAngelis; Jeffrey J. Raizer; Lauren E. Abrey


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
301 KB
Volume
94
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

The current study was conducted to characterize the impact of a prior malignancy on the diagnosis, treatment, and outcome of high‐grade glioma.

METHODS

A retrospective study of 21 patients with a histologic diagnosis of glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), or anaplastic oligodendroglioma (AO) after a prior diagnosis of solid tumor or hematologic malignancy was conducted. Glioma histology (GBM vs. AA/AO), patient age (≀ 60 years vs. > 60 years), and extent of resection (biopsy vs. subtotal vs. complete) were evaluated for their prognostic influence.

RESULTS

Of the 21 patients studied, 17 had GBM, 3 had AA, and 1 patient had high‐grade AO. There were 25 systemic carcinomas diagnosed in 21 patients (18 solid tumors including breast carcinoma, prostate carcinoma, and melanoma and 7 hematologic malignancies). The glioma occurred within a previous radiation field in only three patients, two of whom had solid tumors and one of whom had a childhood hematologic malignancy. Surgical resection was the initial treatment for the brain tumor in 17 patients, and the majority of patients received radiation therapy and adjuvant chemotherapy. Four patients who initially were misdiagnosed as having brain metastases received whole brain radiation therapy as their initial treatment, thereby compromising optimal care. The overall median survival for all the patients in the current study was 14 months (range, 1–44 months) from the time of brain tumor diagnosis. The extent of resection was found to be the only prognostic variable that was associated with survival (P = 0.03).

CONCLUSIONS

Secondary glioma may occur in patients as a consequence of therapy for a prior malignancy, but most often represents a sporadic event. The outcome and recommended treatment are identical to those for patients with primary gliomas. Accurate diagnosis is essential; neuroimaging often is suggestive of a primary brain tumor and should initiate surgical intervention so that histopathology can be obtained early and appropriate treatment instituted. Cancer 2002;94:3219–24. Β© 2002 American Cancer Society.

DOI 10.1002/cncr.10595


πŸ“œ SIMILAR VOLUMES


Pegylated liposomal doxorubicin-efficacy
✍ Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra RΓΌmmele; Oliver Grauer; Annekatri πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 215 KB

## Abstract ## BACKGROUND Doxorubicin exhibits high efficacy in malignant glioma cell cultures. Nonetheless, as a standard formulation, doxorubicin has not been used clinically, due to poor penetration of the blood‐brain barrier. Furthermore, doxorubicin is known to induce tumor resistance genes.

Expression of tissue factor correlates w
✍ Kazuya Hamada; Jun-ichi Kuratsu; Yoshiki Saitoh; Hideo Takeshima; Toru Nishi; Yu πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 735 KB

BACKGROUND. Tissue factor (TF), a cell surface receptor of factor VIIIVIIa, was initially recognized as an initiator of the extrinsic coagulation pathway. TF has recently been found to be expressed highly in certain types of malignant tumors. In addition, TF belongs to the interferon receptor family

MR-monitored LITT as a palliative concep
✍ Peter Reimer; Christoph Bremer; Christoph Horch; Carlo Morgenroth; Thomas Allkem πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 763 KB

The purpose of this study was to evaluate the clinical utility of laser-induced thermotherapy (LITT) as a palliative treatment for patients with high-grade gliomas. Four consenting patients with recurrent high grade III/IV gliomas near the primary language or motor areas were palliatively treated wi